MIYABI ND-C
CKD, anemia
ANEMIA
A total of 153 patients were included in the analysis of the MIYABI ND-C trial (75 for the molidustat group and 78 for the darbepoetin group). In the molidustat group, 96.0% of patients were categorized as having a very high risk for CKD progression, while 83.3% of patients in the darbepoetin group were categorized as having a very high risk. Other baseline characteristics were similar between the two groups (Table Baseline patient characteristics in the MIYABI ND-C trialPatients who had scores at baseline and at least one other timepoint for any of the domains were includedTSQM-II mean domain scores for MIYABI ND-C. Bold indicates significant (The mean change in LS from baseline to each time point showed that patients treated with molidustat showed a nominally significant improvement in the convenience domain at week 12 compared to patients taking darbepoetin alfa (Table Adjusted LS mean changes in TSQM-II scores for each domain at each timepoint and differences across treatment groups (MIYABI ND-C)Patients who had scores at baseline and at least one other time point for any of the domains were included*GEE results for the impact of molidustat on changes in scores across treatment (MIYABI ND-C)Patients who had scores at baseline and at least one other timepoint for any of the domains were included. darbepoetin alfa was the reference treatment arm, and the baseline was the reference time point. Controls included the treatment arm, timepoint category, and baseline characteristics (age, sex, duration of CKD, duration of anemia due to CKD, main cause of CKD, eGFR category (15– < 30 mL/min/1.73 m*